Geben Sie eine Aktie oder eine Kryptowährung in der Suchleiste an, um eine Zusammenfassung zu erhalten
IPCA Laboratories Limited
IPCALABIpca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India. Address: 125, Kandivli Industrial Estate, Mumbai, India, 400067
Analytics
Zielpreis von Wall Street
123 725.21 INRKGV
67.5704Dividendenrendite
0.26 %Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Laufendes Jahr
Letztes Jahr
Laufendes Quartal
Letztes Quartal
Schlüsselzahlen IPCALAB
Dividenden-Analyse IPCALAB
Dividendenwachstum über 5 Jahre
300 %Kontinuierliches Wachstum
–Ausschüttungsquote 5-Jahres-Durchschnitt
13 %Verlauf der Dividende IPCALAB
Bewertung der Aktie IPCALAB
Finanzen IPCALAB
Ergebnisse | 2019 | Dynamik |